Arcus Biosciences, Inc. Free Cash Flow 2016–2025
Arcus Biosciences, Inc. reported $-484.00M of free cash flow for fiscal 2025. That was 175.0% lower than fiscal 2024. Compared with fiscal 2020, the change was -548.1%.
| Fiscal year | Free Cash Flow | Change (YoY) |
|---|---|---|
| FY 2025 | $-484.00M | -175.0% |
| FY 2024 | $-176.00M | +46.7% |
| FY 2023 | $-330.00M | -176.4% |
| FY 2022 | $432.00M | +253.2% |
| FY 2021 | $-282.00M | -361.1% |
| FY 2020 | $108.00M | +243.3% |
| FY 2019 | $-75.39M | -61.3% |
| FY 2018 | $-46.74M | -52.9% |
| FY 2017 | $-30.57M | -79.4% |
| FY 2016 | $-17.04M | — |
Source: Arcus Biosciences, Inc. SEC filings — cash flow statement (10-K). Computed deterministically; refreshed nightly (last updated August 2, 2026). Open RCUS 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Arcus Biosciences, Inc. reported $-484.00M of free cash flow for fiscal 2025. That was 175.0% lower than fiscal 2024. Compared with fiscal 2020, the change was -548.1%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Arcus Biosciences, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeArcus Biosciences, Inc. — frequently asked questions
What is Arcus Biosciences, Inc.'s free cash flow?
Arcus Biosciences, Inc. (RCUS) reported free cash flow of $-484.00M for fiscal year 2025, per its SEC filings.
Where does this data come from?
Figures are computed from Arcus Biosciences, Inc.'s official SEC filings (cash flow statement (10-K)), refreshed nightly. Not investment advice.